Biotech · Private company · Franklin, TN, US
BioSight Ltd.
Track this companyFree. Adds BioSight Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- BST-236Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BST-236Phase 2 · AML, AdultClinicalTrials.gov · fetched Nov 12, 2026
- venetoclaxPhase 2 · AML, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AMLPHASE1_PHASE2 · UNKNOWN · started Aug 17, 2022ClinicalTrials.gov NCT05503355 · fetched Nov 12, 2026
- Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDSPHASE2 · UNKNOWN · started Nov 14, 2021ClinicalTrials.gov NCT04749355 · fetched Nov 12, 2026
- Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction TherapyPHASE2 · COMPLETED · started Aug 14, 2018ClinicalTrials.gov NCT03435848 · fetched Nov 12, 2026
NIH awards1
- Neurofluid Biomarkers for Clinical Trials of NeurodegenerationFiscal year 2026 · $238.3KNIH RePORTER 1R41AG099493-01A1 · fetched Nov 12, 2026